There is uncertainty regarding the degree of insurance risk associated with BRCA1/2, the gene mutations associated with breast cancer. Most reports to date have been based on high-risk populations selected from families with multiple and/or early-onset cancers; more favorable data have been reported in studies without this selection bias.This paper discusses use of a Markov model to estimate mortality risk associated with BRCA1/2 gene mutations in female life insurance applicants. The goal is to derive a range of risk estimates based on different assumptions of breast and ovarian cancer incidence. A particular strength of the model is that transition probabilities after cancer diagnosis vary with age and cancer stage, as do excess hazard rates.Data calculated by the model indicate that no single mortality curve characterizes risk for all life insurance applicants with a BRCA1/2 mutation. Rather, mortality risk depends on breast and ovarian cancer incidence rates and subsequent mortality rates, and on the method used to deal with competing breast and ovarian cancer incidence and mortality rates. Further refinement of risk estimates will depend on better incidence data and on resolution of complex statistical problems, such as informative censoring.Widespread use of genetic information by insurance consumers could have important economic implications. For companies that sell individually underwritten products, profitability might decrease. Consumers might find higher prices and reduced availability, with a corresponding decrease in quantity of insurance purchased. Insurance and consumer ramifications would vary by cover, with living-benefit products, such as critical-illness insurance, most adversely affected. Societal choices are limited. Given assumptions in the cited scenario, it is likely premiums would rise and quantity of insurance purchased would decrease even with no change in existing social policy; attempted legal or regulatory remedies would further accentuate price increases and reductions in quantity purchased.